|
Aug 30
|
Merus NV (MRUS): Top ADR Stock According to Hedge Funds
|
|
Jul 29
|
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 24
|
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
|
|
May 30
|
Merus Announces Pricing of Upsized Public Offering of Common Shares
|
|
May 29
|
These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
|
|
May 29
|
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
|
|
May 28
|
Merus N.V. Announces Proposed Public Offering of Common Shares
|
|
May 28
|
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
|
|
May 27
|
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
|
|
May 24
|
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
|
|
May 24
|
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
|
|
May 24
|
Merus Clears Wall Street's Bar With Cancer Data
|
|
May 24
|
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities
|
|
May 24
|
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
|
|
May 24
|
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
|
|
May 23
|
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
|
|
May 23
|
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
|
|
May 13
|
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
|
|
May 11
|
Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
|
|
May 10
|
Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame
|